322 related articles for article (PubMed ID: 32587099)
21. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
22. CYP3A4 is a major isoform responsible for oxidation of 7-hydroxy-Delta(8)-tetrahydrocannabinol to 7-oxo-delta(8)-tetrahydrocannabinol in human liver microsomes.
Matsunaga T; Kishi N; Higuchi S; Watanabe K; Ohshima T; Yamamoto I
Drug Metab Dispos; 2000 Nov; 28(11):1291-6. PubMed ID: 11038155
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.
Anderson GD; Chan LN
Clin Pharmacokinet; 2016 Nov; 55(11):1353-1368. PubMed ID: 27106177
[TBL] [Abstract][Full Text] [Related]
24. Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid-Oxazepam Drug Interactions.
Bardhi K; Coates S; Chen G; Lazarus P
Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399297
[TBL] [Abstract][Full Text] [Related]
25. Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.
Klein C; Karanges E; Spiro A; Wong A; Spencer J; Huynh T; Gunasekaran N; Karl T; Long LE; Huang XF; Liu K; Arnold JC; McGregor IS
Psychopharmacology (Berl); 2011 Nov; 218(2):443-57. PubMed ID: 21667074
[TBL] [Abstract][Full Text] [Related]
26. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
[TBL] [Abstract][Full Text] [Related]
27. Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies.
Ericsson T; Sundell J; Torkelsson A; Hoffmann KJ; Ashton M
Xenobiotica; 2014 Jul; 44(7):615-26. PubMed ID: 24400699
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites.
Nasrin S; Watson CJW; Bardhi K; Fort G; Chen G; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1081-1089. PubMed ID: 34493601
[TBL] [Abstract][Full Text] [Related]
29. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Lu C; Suri A; Shyu WC; Prakash S
Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
[TBL] [Abstract][Full Text] [Related]
30. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.
Yamaori S; Kushihara M; Yamamoto I; Watanabe K
Biochem Pharmacol; 2010 Jun; 79(11):1691-8. PubMed ID: 20117100
[TBL] [Abstract][Full Text] [Related]
31. NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition.
Kosaka M; Zhang D; Wong S; Yan Z
Drug Metab Dispos; 2020 Aug; 48(8):655-661. PubMed ID: 32482757
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions.
Coates S; Bardhi K; Lazarus P
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543313
[TBL] [Abstract][Full Text] [Related]
33. Psychotropic and nonpsychotropic cannabis derivatives inhibit human 5-HT(3A) receptors through a receptor desensitization-dependent mechanism.
Xiong W; Koo BN; Morton R; Zhang L
Neuroscience; 2011 Jun; 184():28-37. PubMed ID: 21477640
[TBL] [Abstract][Full Text] [Related]
34. Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug-drug interactions involving canine cytochrome P-450, UDP-glucuronosyltransferase, and P-glycoprotein.
Court MH; Mealey KL; Burke NS; Jimenez TP; Zhu Z; Wakshlag JJ
J Vet Pharmacol Ther; 2024 Jan; 47(1):1-13. PubMed ID: 37469115
[TBL] [Abstract][Full Text] [Related]
35. Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
Wolowich WR; Greif R; Kleine-Brueggeney M; Bernhard W; Theiler L
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):691-711. PubMed ID: 31114948
[TBL] [Abstract][Full Text] [Related]
36. Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitors.
Kahma H; Paludetto MN; Neuvonen M; Kurkela M; Filppula AM; Niemi M; Backman JT
Eur J Pharm Sci; 2024 Jul; 198():106735. PubMed ID: 38423227
[TBL] [Abstract][Full Text] [Related]
37. Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method.
Yang X; Atkinson K; Di L
Drug Metab Dispos; 2016 Mar; 44(3):460-5. PubMed ID: 26700955
[TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics and the pharmacodynamics of cannabinoids.
Lucas CJ; Galettis P; Schneider J
Br J Clin Pharmacol; 2018 Nov; 84(11):2477-2482. PubMed ID: 30001569
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of Action and Pharmacokinetics of Cannabis.
Chayasirisobhon S
Perm J; 2020 Dec; 25():1-3. PubMed ID: 33635755
[TBL] [Abstract][Full Text] [Related]
40. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
